Biologic Therapies IV
TNF Failures:
Sorting Out the Options
 |
||
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Release Date: June 24, 2011
Expiration Date: June 24, 2013
Estimated Time of Completion: 30 minutes
Description
Biologic Therapies IV: Webcast Series is a compilation of live presentations recorded at the Biologic Therapies Summit IV: Current and Emerging Indications. This webcast series continues a successful tradition of presenting innovative, quality presentations that provide evidence-based, practical knowledge to fulfill participants' educational objectives. An international faculty of experts who span a multitude of scientific disciplines will provide their insights on a variety of timely topics, including the following:
- Research advances in immunodeficiencies and autoimmunity,
- Approved biologic agents and clinical trial data,
- Development of new biologic agents,
- Toxicities associated with biologic agents,
- Clinical implications and potential new indications.
Learning Objectives
- List the strategies to improve outcomes in TNF inadequate responders.
- Identify the appropriate timing for switching biologics for lack of efficacy.
- Recognize the role of biologics in TNF-IRs.
Target Audience
This activity is directed to rheumatologists, gastroenterologists, dermatologists, pulmonologists, internal medicine physicians, nurse practitioners, physician assistants, and other health care professionals interested in or using biologic therapies in autoimmune and inflammatory disorders.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director
Leonard Calabrese, DO
Professor of Medicine
Cleveland Clinic Lerner College of Medicine
of Case Western Reserve University
Vice Chairman
Department of Rheumatic & Immunologic Diseases
R.J. Fasenmyer Chair of Clinical Immunology
Orthopaedic & Rheumatologic Institute
Cleveland Clinic
Cleveland, OH
Faculty
Edward Keystone, MD, FRCPC
Professor of Medicine
University of Toronto
Director, Rebecca MacDonald Centre for Arthritis and Autoimmune Disease
Mount Sinai Hospital
Toronto, Canada
Disclosures
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty have indicated that they may have a relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:
| Leonard Calabrese, DO | ||
| Consulting: |
BMS; Elan Pharmaceuticals, Inc; Wyeth |
|
| Consulting, Teaching & Speaking: |
Abbott Laboratories; Amgen; Centocor; Genentech/Roche; Pfizer |
|
| Edward Keystone, MD, PhD | ||
| Consulting/Teaching and Speaking/BoardMembership - Membership on advisory committee or review panels: |
Abbott Laboratories; Amgen; Bristol-Myers Squibb Co.; Centocor; Roche Laboratories; Schering Plough/Merck; UCB |
|
The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational
grants for partial support of this activity from:
Abbott Laboratories Inc.,
Amgen, Inc.,
Bristol-Myers Squibb,
Centocor Ortho Biotech Services, LLC,
Genentech, Inc. and Biogen Idec,
UCB, Inc.
This CME activity was produced by The Cleveland Clinic Foundation Center for Continuing Education and the
R.J. Fasenmyer Center for Clinical Immunology.
